Key result
Compared with placebo, 60 mg oral nimodipine reduced very-low-frequency mean arterial blood pressure (P<0.05) and middle cerebral artery flow velocity power (P<0.01) in healthy humans.
Why the study?
The relationships between blood pressure variability and cerebral blood flow variability across individuals in the presence of intact and blunted cerebrovascular control are poorly understood.
Does oral nimodipine alter the relationship between blood pressure variability and cerebral blood flow variability in healthy humans?
RCT (n=23)
Does oral nimodipine alter the relationship between blood pressure variability and cerebral blood flow variability in healthy humans?
Cerebral blood flow variability is positively correlated with blood pressure variability, and calcium channel blockade with nimodipine can reduce very-low-frequency variability in both parameters.
CFV may link BPV to cerebrovascular risk in healthy adults; leaves open CCB effects on outcomes in patients.
The relationships between blood pressure variability (BPV) and cerebral blood flow variability (CFV) across individuals in the presence of intact and blunted cerebrovascular control are poorly understood. This study sought to characterize the interindividual associations between spontaneous BPV and CFV under conditions of normal and blunted [calcium channel blockade (CCB)] cerebrovascular control in healthy humans. We analyzed blood pressure and flow velocity data from 12 subjects treated with CCB (60 mg oral nimodipine) and 11 subjects treated with a placebo pill. Spontaneously occurring fluctuations in mean arterial blood pressure (MAP) and middle cerebral artery flow velocity (MCAv(mean); transcranial Doppler) were characterized using power spectral and transfer function analysis in the very-low- (0.02-0.07 Hz), low- (0.07-0.20 Hz), and high-frequency (0.20-0.40 Hz) ranges. Across our study sample, MAP and MCAv(mean) power were positively correlated in all three frequency ranges, both before (R(2) = 0.34-0.67, all P < 0.01) and after CCB (R(2) = 0.53-0.61, all P < 0.02). Compared with placebo, CCB reduced very-low-frequency MAP (P < 0.05) and MCAv(mean) power (P < 0.01) and the low-frequency cross-spectral phase angle (P < 0.05). The magnitude of change in MAP and MCAv(mean) power with CCB (i.e., change scores) was positively related in the very-low-frequency range. Collectively, these findings indicate that CFV may be an explanatory factor in the association between elevated BPV and adverse cerebrovascular outcomes and support the possibility of using CCB to improve hemodynamic stability under resting conditions.
No takes yet. Share an insight, caveat, or question.
Tzeng et al. (2013) conducted an RCT in Healthy (n=23). Nimodipine vs. Placebo was evaluated on Very-low-frequency mean arterial blood pressure (MAP) and middle cerebral artery flow velocity (MCAv) power (p=<0.05). Compared with placebo, 60 mg oral nimodipine reduced very-low-frequency mean arterial blood pressure (P<0.05) and middle cerebral artery flow velocity power (P<0.01) in healthy humans.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: